Developer docs
API playgroundTry for free, no card

Search company profiles

INTRA-KER

Full company profile

uuid006dfa9

Namestring
INTRA-KER
Legal namestring
INTRA-KER Srl
Websiteurl
intra-ker.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

INTRA-KER is an Italian clinical-stage medtech company, spun out of the University of Ferrara (UNIFE), developing a hybrid artificial cornea (keratoprosthesis) for patients with severe corneal blindness who are not candidates for conventional donor transplantation. The company's core technology centers on a patented biological wrap designed to overcome the principal failure modes of existing artificial corneas — retroprosthetic membrane formation, tissue melt, and chronic inflammation — which currently drive complication rates as high as 70% and leave roughly half of recipients legally blind within one year. The device targets the estimated 12.7 million patients worldwide awaiting corneal transplants and the roughly 8,000 annual cases in which donor grafts fail, an addressable population that is structurally underserved by the limited global supply of 185,000 donor transplants per year.

The company is led by Professor Massimo Busin (President and CEO), a high-volume corneal surgeon, with Angeli Christy Yu (MD, PhD) as CTO and Vittorio Guarini handling business development contacts. INTRA-KER has built a multi-partner ecosystem including Eliachar Technology for surgical instrumentation, Fondazione Banca degli Occhi del Veneto for tissue supply, LIRFO and UNIFE for clinical and academic collaboration, and XPANCEO for a follow-on "smart cornea" platform. The company obtained Italian Ministry of Health authorization for clinical investigation in October 2025 and is scheduled to begin a clinical trial on 30 identified patients in November 2025, following a first-in-human transplant performed in October 2024 on a Palestinian refugee patient.

INTRA-KER is pre-revenue and is raising its first external funding round of €1.5 million, with approximately 85% allocated to R&D and clinical trial execution. Its intended go-to-market is a regulated Class III implantable device sold to hospitals and ophthalmology centers on a per-procedure basis, with CE marking under EU-MDR as the likely first commercial milestone. The business model hinges on converting clinical-trial success into premium-pricing reimbursement for a device positioned against both donor tissue and inferior existing keratoprostheses.

Short descriptiontext

INTRA-KER is an Italian clinical-stage medtech spin-off from the University of Ferrara developing a patented hybrid artificial cornea (keratoprosthesis) for patients with severe corneal blindness who lack alternatives to donor transplantation.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersForlì, Italy
HQ citystring
Forlì
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
artificial cornea implants, hybrid keratoprosthesis, ophthalmic medical devices, corneal blindness treatment, intracorneal devices
Industry3 codes
PRIMARYHLAHAJAK
Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAAAGAK
Ophthalmic Regeneration (cornea/retina)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAKAKAF
Cornea, External Disease & Refractive Surgery (LASIK/PRK)
SIC code1 code
  • Optical Instruments & Lenses3827
Product category
Ophthalmic Medical Devices
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Commercialization
TypeOne Time License
Description

Pre-revenue clinical stage company. Revenue model will be derived from the sale of hybrid artificial cornea devices to hospitals and ophthalmology centers upon regulatory approval.

intra-ker.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

INTRA-KER develops and is clinically validating a hybrid intracorneal device (hybrid artificial cornea) for corneal transplantation. The device combines a patented optical component with a biological wrap that integrates with host tissue, addressing limitations of traditional corneal transplants including immune rejection, endothelial cell loss, infection risk, and donor cornea scarcity. The company is conducting human clinical studies in Italy following Ministry of Health approval.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Over 185,000 corneal transplants performed annually using traditional methods globally
+4 more records
Product overview1 text field

INTRA-KER is a clinical-stage medtech company developing a single unified product: the INTRA-KER Hybrid Intracorneal Device (hybrid artificial cornea). This device combines a patented optical component with a biological wrap that integrates with host tissue. The company is also collaborating with XPANCEO on a future 'smart cornea' that would incorporate electronic capabilities to project images onto the retina. The current hybrid device is designed as an alternative to traditional corneal transplantation, addressing limitations including immune rejection, scarcity of donor tissue, and high complication rates.

Product and service1 record
1INTRA-KER Hybrid Intracorneal Device (Hybrid Artificial Cornea)
CategoryOphthalmic Medical Devices
Description

A hybrid intracorneal device (keratoprosthesis) combining a patented optical component with a biological wrap for corneal transplantation. The device is extraocular for safe implantation, stable allowing storage over 12 months, transparent for light transmission, acellular to obviate immune rejection risk, biologic for stable bio-integration, and independent of endothelial function. Designed for hospitals and ophthalmology centers treating patients with corneal blindness who cannot be treated by traditional donor cornea transplantation.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-03
Description

Strategic collaboration with XPANCEO, a deep tech company pioneering optical and electronic integration. Together the companies aim to evolve the hybrid cornea into a future 'smart cornea' capable of restoring and even enhancing vision. The collaboration has produced an intracorneal implant prototype that projects images onto the retina, representing a significant advancement in vision restoration technology.

Strategic tierCoreTypeTechnology or Integration
Description

R&D partnership for applied research on the use of optical lenses and projectors to replace the diseased cornea. Eliachar Technology collaborated with INTRA-KER beginning in 2021 for initial R&D phase development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

The Venice Eye Bank (Fondazione Banca degli Occhi del Veneto) partnered with INTRA-KER for the presentation of the first Italian Hybrid Keratoprosthesis. This partnership validates the technology through established ophthalmology institutions.

4University of Ferrara (UNIFE)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

INTRA-KER is a UNIFE spin-off company, indicating a formal academic partnership for research and development of the hybrid corneal prosthesis technology.

intra-ker.com
5LIRFO (Istituto Internazionale di Ricerca Formazione Orientamento)
Strategic tierMinorTypeOthers
Description

Listed as a partner organization on the INTRA-KER About page, representing an international research and training institute collaboration.

intra-ker.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Keramed manufactures the KeraKlear artificial cornea, a foldable keratoprosthesis directly competing with INTRA-KER's hybrid intracorneal device in the corneal blindness segment. Both target patients unsuitable for traditional donor transplantation and pursue similar regulatory and surgeon-training pathways.

2BostonSight
TypeDirect peer
Description

BostonSight is associated with the Boston Keratoprosthesis (Boston KPro), the most widely implanted FDA-cleared artificial cornea globally and INTRA-KER's primary benchmark for clinical performance. It serves the same end-patient population (severe corneal disease) and competes for surgeon adoption in the same ophthalmology centers.

TypeEmerging player
Description

Aurolab manufactures the AuroKPro, a low-cost keratoprosthesis designed for emerging markets where donor tissue is most scarce. INTRA-KER's hybrid device competes in the same value-based segment and is likely to be benchmarked against AuroKPro on cost in developing-market expansion.

TypeBroad incumbent
Description

Alcon is the largest dedicated ophthalmology device company globally, with a broad cataract, refractive, and surgical portfolio. It represents the most likely large strategic acquirer for a successful keratoprosthesis asset and the dominant commercial channel for any approved corneal device.

TypeDirect peer
Description

LinkoCare is developing the LinkCor artificial cornea, a synthetic, cell-free keratoprosthesis that mirrors INTRA-KER's positioning on acellular, donor-independent corneal replacement. It is one of the closest mechanistic analogues to INTRA-KER's hybrid design.

TypeBroad incumbent
Description

CorneaGen is a leading eye-bank and corneal tissue provider serving transplant surgeons globally. As a dominant donor-cornea supplier, it represents both a complement and competitive incumbent whose network and surgeon relationships INTRA-KER must navigate for adoption.

7Carl Zeiss Meditec AG
TypeBroad incumbent
Description

Carl Zeiss Meditec is a global ophthalmic device incumbent offering surgical microscopes, IOLs, and laser systems used alongside corneal transplantation. While not a direct artificial-cornea competitor, it is a potential strategic acquirer and controls key distribution channels INTRA-KER would need to access.

TypeDirect peer
Description

DIOPTEX develops and distributes artificial corneas (including the KPro line) for corneal blindness, positioning it as a direct product competitor in the European keratoprosthesis market where INTRA-KER also operates.

TypeBroad incumbent
Description

Bausch + Lomb is a diversified ophthalmology player covering surgical, vision care, and pharmaceuticals. It is a relevant strategic acquirer and competing portfolio company whose keratoprosthesis partnerships and surgical channels could overlap with INTRA-KER's go-to-market.

TypeEmerging player
Description

Precise Bio is advancing 3D bio-printed corneal grafts targeting endothelial and full-thickness corneal disease. While their modality differs (printed tissue vs. synthetic hybrid), they address the same donor-shortage unmet need and compete for the same ophthalmology centers and venture capital.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

INTRA-KER

Ophthalmic Medical Devicesintra-ker.com

INTRA-KER is an Italian clinical-stage medtech spin-off from the University of Ferrara developing a patented hybrid artificial cornea (keratoprosthesis) for patients with severe corneal blindness who lack alternatives to donor transplantation.

What INTRA-KER does

INTRA-KER is an Italian clinical-stage medtech company, spun out of the University of Ferrara (UNIFE), developing a hybrid artificial cornea (keratoprosthesis) for patients with severe corneal blindness who are not candidates for conventional donor transplantation. The company's core technology centers on a patented biological wrap designed to overcome the principal failure modes of existing artificial corneas — retroprosthetic membrane formation, tissue melt, and chronic inflammation — which currently drive complication rates as high as 70% and leave roughly half of recipients legally blind within one year. The device targets the estimated 12.7 million patients worldwide awaiting corneal transplants and the roughly 8,000 annual cases in which donor grafts fail, an addressable population that is structurally underserved by the limited global supply of 185,000 donor transplants per year.

The company is led by Professor Massimo Busin (President and CEO), a high-volume corneal surgeon, with Angeli Christy Yu (MD, PhD) as CTO and Vittorio Guarini handling business development contacts. INTRA-KER has built a multi-partner ecosystem including Eliachar Technology for surgical instrumentation, Fondazione Banca degli Occhi del Veneto for tissue supply, LIRFO and UNIFE for clinical and academic collaboration, and XPANCEO for a follow-on "smart cornea" platform. The company obtained Italian Ministry of Health authorization for clinical investigation in October 2025 and is scheduled to begin a clinical trial on 30 identified patients in November 2025, following a first-in-human transplant performed in October 2024 on a Palestinian refugee patient.

INTRA-KER is pre-revenue and is raising its first external funding round of €1.5 million, with approximately 85% allocated to R&D and clinical trial execution. Its intended go-to-market is a regulated Class III implantable device sold to hospitals and ophthalmology centers on a per-procedure basis, with CE marking under EU-MDR as the likely first commercial milestone. The business model hinges on converting clinical-trial success into premium-pricing reimbursement for a device positioned against both donor tissue and inferior existing keratoprostheses.

INTRA-KER firmographics

Firmographics
Name
INTRA-KER
Legal name
INTRA-KER Srl
Website
https://intra-ker.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
INTRA-KER is an Italian clinical-stage medtech spin-off from the University of Ferrara developing a patented hybrid artificial cornea (keratoprosthesis) for patients with severe corneal blindness who lack alternatives to donor transplantation.
Ownership category
akta.pro rank

INTRA-KER industry classification

Industry
Product category
Ophthalmic Medical Devices
SIC
Optical Instruments & Lenses (3827)
akta.pro industry
PRIMARYHLAHAJAK
Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAAAGAK
Ophthalmic Regeneration (cornea/retina)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAKAKAF
Cornea, External Disease & Refractive Surgery (LASIK/PRK)

Keywords

  • Artificial cornea implants
  • Hybrid keratoprosthesis
  • Ophthalmic medical devices
  • Corneal blindness treatment
  • Intracorneal devices

Where INTRA-KER is headquartered

Location

Headquarters

HQ city
Forlì
HQ country
Italy
HQ region
Europe

Offices1 record

Markets served

INTRA-KER business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Medical Device Commercialization: Pre-revenue clinical stage company. Revenue model will be derived from the sale of hybrid artificial cornea devices to hospitals and ophthalmology centers upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

INTRA-KER product offering

Product offering

Core offering

INTRA-KER develops and is clinically validating a hybrid intracorneal device (hybrid artificial cornea) for corneal transplantation. The device combines a patented optical component with a biological wrap that integrates with host tissue, addressing limitations of traditional corneal transplants including immune rejection, endothelial cell loss, infection risk, and donor cornea scarcity. The company is conducting human clinical studies in Italy following Ministry of Health approval.

Product overview

INTRA-KER is a clinical-stage medtech company developing a single unified product: the INTRA-KER Hybrid Intracorneal Device (hybrid artificial cornea). This device combines a patented optical component with a biological wrap that integrates with host tissue. The company is also collaborating with XPANCEO on a future 'smart cornea' that would incorporate electronic capabilities to project images onto the retina. The current hybrid device is designed as an alternative to traditional corneal transplantation, addressing limitations including immune rejection, scarcity of donor tissue, and high complication rates.

Differentiator

Problem solved

Functional benefit

Products and services

  • INTRA-KER Hybrid Intracorneal Device (Hybrid Artificial Cornea) A hybrid intracorneal device (keratoprosthesis) combining a patented optical component with a biological wrap for corneal transplantation. The device is extraocular for safe implantation, stable allowing storage over 12 months, transparent for light transmission, acellular to obviate immune rejection risk, biologic for stable bio-integration, and independent of endothelial function. Designed for hospitals and ophthalmology centers treating patients with corneal blindness who cannot be treated by traditional donor cornea transplantation.

Quantifiable outcome

  • Over 185,000 corneal transplants performed annually using traditional methods globally
  • +4 more outcomes

Companies that use INTRA-KER

Customer profile

Named customers2 records

Segments1 record

Ideal customer profiles2 records

INTRA-KER technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

INTRA-KER partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • XPANCEOcoreStrategic or Co-development Partner · 3 September 2025Strategic collaboration with XPANCEO, a deep tech company pioneering optical and electronic integration. Together the companies aim to evolve the hybrid cornea into a future 'smart cornea' capable of restoring and even enhancing vision. The collaboration has produced an intracorneal implant prototype that projects images onto the retina, representing a significant advancement in vision restoration technology.
  • Eliachar TechnologycoreTechnology or IntegrationR&D partnership for applied research on the use of optical lenses and projectors to replace the diseased cornea. Eliachar Technology collaborated with INTRA-KER beginning in 2021 for initial R&D phase development.
  • Fondazione Banca degli Occhi del VenetocoreStrategic or Co-development PartnerThe Venice Eye Bank (Fondazione Banca degli Occhi del Veneto) partnered with INTRA-KER for the presentation of the first Italian Hybrid Keratoprosthesis. This partnership validates the technology through established ophthalmology institutions.
  • University of Ferrara (UNIFE)coreStrategic or Co-development PartnerINTRA-KER is a UNIFE spin-off company, indicating a formal academic partnership for research and development of the hybrid corneal prosthesis technology.
  • LIRFO (Istituto Internazionale di Ricerca Formazione Orientamento)minorOthersListed as a partner organization on the INTRA-KER About page, representing an international research and training institute collaboration.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

INTRA-KER competitors and assessment

Company assessment

Direct peers

  • Keramed Inc. Keramed manufactures the KeraKlear artificial cornea, a foldable keratoprosthesis directly competing with INTRA-KER's hybrid intracorneal device in the corneal blindness segment. Both target patients unsuitable for traditional donor transplantation and pursue similar regulatory and surgeon-training pathways.
  • BostonSight: BostonSight is associated with the Boston Keratoprosthesis (Boston KPro), the most widely implanted FDA-cleared artificial cornea globally and INTRA-KER's primary benchmark for clinical performance. It serves the same end-patient population (severe corneal disease) and competes for surgeon adoption in the same ophthalmology centers.
  • LinkoCare Life Sciences AB: LinkoCare is developing the LinkCor artificial cornea, a synthetic, cell-free keratoprosthesis that mirrors INTRA-KER's positioning on acellular, donor-independent corneal replacement. It is one of the closest mechanistic analogues to INTRA-KER's hybrid design.
  • DIOPTEX Medizinprodukte Forschungs- und Vertriebs GmbH: DIOPTEX develops and distributes artificial corneas (including the KPro line) for corneal blindness, positioning it as a direct product competitor in the European keratoprosthesis market where INTRA-KER also operates.

Emerging players

  • Aurolab: Aurolab manufactures the AuroKPro, a low-cost keratoprosthesis designed for emerging markets where donor tissue is most scarce. INTRA-KER's hybrid device competes in the same value-based segment and is likely to be benchmarked against AuroKPro on cost in developing-market expansion.
  • Precise Bio: Precise Bio is advancing 3D bio-printed corneal grafts targeting endothelial and full-thickness corneal disease. While their modality differs (printed tissue vs. synthetic hybrid), they address the same donor-shortage unmet need and compete for the same ophthalmology centers and venture capital.

Broad incumbents

  • Alcon Inc. Alcon is the largest dedicated ophthalmology device company globally, with a broad cataract, refractive, and surgical portfolio. It represents the most likely large strategic acquirer for a successful keratoprosthesis asset and the dominant commercial channel for any approved corneal device.
  • CorneaGen: CorneaGen is a leading eye-bank and corneal tissue provider serving transplant surgeons globally. As a dominant donor-cornea supplier, it represents both a complement and competitive incumbent whose network and surgeon relationships INTRA-KER must navigate for adoption.
  • Carl Zeiss Meditec AG: Carl Zeiss Meditec is a global ophthalmic device incumbent offering surgical microscopes, IOLs, and laser systems used alongside corneal transplantation. While not a direct artificial-cornea competitor, it is a potential strategic acquirer and controls key distribution channels INTRA-KER would need to access.
  • Bausch + Lomb (Bausch Health): Bausch + Lomb is a diversified ophthalmology player covering surgical, vision care, and pharmaceuticals. It is a relevant strategic acquirer and competing portfolio company whose keratoprosthesis partnerships and surgical channels could overlap with INTRA-KER's go-to-market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

INTRA-KER financial estimates

Financial estimate

Revenue estimate

Valuation estimate

INTRA-KER leadership team

Management profile

Number of profiles

Profiles2 records

INTRA-KER funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

INTRA-KER M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about INTRA-KER

What does INTRA-KER do?

INTRA-KER develops and is clinically validating a hybrid intracorneal device (hybrid artificial cornea) for corneal transplantation. The device combines a patented optical component with a biological wrap that integrates with host tissue, addressing limitations of traditional corneal transplants including immune rejection, endothelial cell loss, infection risk, and donor cornea scarcity. The company is conducting human clinical studies in Italy following Ministry of Health approval.

Is INTRA-KER a public or private company?

INTRA-KER is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was INTRA-KER founded?

INTRA-KER was founded in 2020. It employs 1 to 10 people.

Where is INTRA-KER based?

INTRA-KER is headquartered in Forlì, Italy, in the Europe region.

How does INTRA-KER make money?

One revenue line is on record: medical Device Commercialization.

Who are INTRA-KER's main competitors?

Direct peers on record are Keramed Inc., BostonSight, LinkoCare Life Sciences AB and DIOPTEX Medizinprodukte Forschungs- und Vertriebs GmbH. Emerging players are Aurolab and Precise Bio. Broad incumbents are Alcon Inc., CorneaGen, Carl Zeiss Meditec AG and Bausch + Lomb (Bausch Health).

Does INTRA-KER have an API?

No public API is recorded for INTRA-KER.

What industry is INTRA-KER in?

INTRA-KER's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAK, Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery), with a secondary code of HLAAAGAK, Ophthalmic Regeneration (cornea/retina). Its SIC code is 3827.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales